Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by WatchLearnEarnon Mar 20, 2018 10:39pm

83 Views

Post# 27750912

RE:Another surprise.

Where do these semi-literate things come from? Crawl back under your rock, worm. quote=AlgAlg]...with the Hype that was being created with the possibility of positive results for ATE........it basically doubled. Am not so sure that this is all it is made out to be. When the Doctors around the World and cutting out Opiods, don’t you think that ATE would be the ‘saving grace’....

Seems not for some reason.......just an opinion. Yes I doubled my
Great But....?[/quote]

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale